-+ 0.00%
-+ 0.00%
-+ 0.00%

Cardiol Therapeutics receives over USD 7 million from warrant exercises

PUBT·09/16/2026 11:27:27
Listen to the news
Cardiol Therapeutics receives over USD 7 million from warrant exercises
  • Cardiol Therapeutics received over USD 7 million from exercises of outstanding common share purchase warrants.
  • Cash runway now extends into H1 2028 ahead of the Phase III MAVERIC topline data readout in recurrent pericarditis.
  • Warrants are subject to an acceleration right triggered as of Sept. 15, 2026.
  • 425,000 warrants remained unexercised, implying additional potential gross proceeds of USD 573,750.
  • Accelerated warrants will expire at 4:00 p.m. ET on Oct. 16, 2026; unexercised warrants will be cancelled.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202609160727CANADANWCANADAPR_C2905) on September 16, 2026, and is solely responsible for the information contained therein.